IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
BOLD News
Archived Headlines
- Oncology biotech Boundless Bio files for a $100 million IPO 03/06/24
- US IPO Weekly Recap: Three profitable companies deliver double-digit returns 07/22/16
- OrbiMed-backed Audentes Therapeutics prices IPO at $15, within the range 07/19/16
- US IPO Week Ahead: Three profitable IPOs and a biotech look to raise $900 million 07/15/16
- US IPO Weekly Recap: LINE and AdvancePierre trade up on market debut 07/15/16
See more
US IPO Weekly Recap: Biotech leads short 3 IPO week
Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings. Phase 1 oncology biotech Boundless Bio (BOLD) raised $100 million at a $396 million market cap. The company is focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Its lead ecDTx, BBI-355, is a novel, oral, selective...read more
Oncology biotech Boundless Bio prices IPO at $16 midpoint
Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors, raised $100 million by offering 6.3 million shares at $16, within the range of $15 to $17. Boundless Bio is focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, the company identifies...read more
US IPO Week Ahead: Oncology biotech leads 3 IPO week
Three listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week. Phase 1 oncology biotech Boundless Bio (BOLD) plans to raise $100 million at a $396 million market cap. The company is focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Its lead ecDTx,...read more
Oncology biotech Boundless Bio sets terms for $100 million IPO
Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors, announced terms for its IPO on Thursday. The San Diego, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Boundless Bio would command a fully diluted market value of $396 million. Boundless...read more